Alisertib (MLN8237)

Catalog No.S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 46 Publications

10 Customer Reviews

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

    Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

  • Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

    Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
Features First orally available inhibitor of Aurora A.
Targets
Aurora A [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
1.2 nM 396.5 nM
In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXvV5AxNjVizszN NGTBdmM4OiCq NEm0eJVFVVOR NImwZmxKSzVyPUCuNFQh|ryP NU\5cmsyOjZzM{[2PFQ>
LS174T M3HYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWK2VFFbOC53IN88US=> Mn[1O|IhcA>? NXLY[2dlTE2VTx?= NIjB[4JKSzVyPUCuNFUh|ryP M2e1RVI3OTN4Nki0
T84 NGT1SpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV35UppyOC53IN88US=> M{DhXVczKGh? NYPue2o{TE2VTx?= MkHrTWM2OD1yLkC5JO69VQ>? MYWyOlE{PjZ6NB?=
LS180 M3XnWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTINE42KM7:TR?= NVz2fFJGPzJiaB?= M4raOmROW09? M2i1VGlEPTB;MTFOwG0> M{TBXFI3OTN4Nki0
SW948 NFXnNWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HhT|AvPSEQvF2= MoO5O|IhcA>? Ml\oSG1UVw>? NYLnNWdLUUN3ME2xJO69VQ>? MoLDNlYyOzZ4OES=
HCT15 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOwMlUh|ryP NF[y[VY4OiCq NFTOVpBFVVOR MmL4TWM2ODxyLkSg{txO NILwV3QzPjF|Nk[4OC=>
DLD-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7NSGNxOC53IN88US=> MVe3NkBp MUHEUXNQ NUPlTnFnUUN3MEywMlgh|ryP NWLMSXptOjZzM{[2PFQ>
MIP-101 MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfWNIQxNjVizszN MnLFO|IhcA>? NF;ObG5FVVOR NGTx[WZKSzVyPUGg{txO NVGxN3V3OjZzM{[2PFQ>
SNU1544 MlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vtTVAvPSEQvF2= NF6yOno4OiCq NHLKTYJFVVOR MXXJR|UxRTFizszN NYruRZhNOjZzM{[2PFQ>
OCI-Ly10 NF6zelFEgXSxdH;4bYMhSXO|YYm= MlWxO|IhcA>? MoPmSG1UVw>? MVXJR|UxRTBwMEW4JO69VQ>? M3LIbFI2QDd6M{Ox
SU-DHL2 NV3jT21CS3m2b4TvfIlkKEG|c3H5 NXzkRmZVPzJiaB?= MnXSSG1UVw>? NFfX[lRKSzVyPUCuNFEh|ryP NULBe3pkOjV6N{izN|E>
OCI-LY7 MlvlR5l1d3SxeHnjJGF{e2G7 NHK0VJo4OiCq MYHEUXNQ Mnv4TWM2OD1yLkC4NUDPxE1? NWTTVGJGOjV6N{izN|E>
SU-DHL6 MX3DfZRwfG:6aXOgRZN{[Xl? NYGybXJTPzJiaB?= MVvEUXNQ MWHJR|UxRTBwNEiyJO69VQ>? MoPtNlU5Pzh|M{G=
Jeko-1 MVLDfZRwfG:6aXOgRZN{[Xl? MkntO|IhcA>? MWjEUXNQ NF35XoNKSzVyPUCuNFI6KM7:TR?= MmnpNlU5Pzh|M{G=
JVM-2 NHz2OVdEgXSxdH;4bYMhSXO|YYm= MV63NkBp NH3BUW1FVVOR NYDHd21rUUN3ME2wMlAyKM7:TR?= MXeyOVg4QDN|MR?=
Rec-1 MXXDfZRwfG:6aXOgRZN{[Xl? NILoSok4OiCq NYHBWXZjTE2VTx?= MUXJR|UxRTBwMEi3JO69VQ>? NWHVVXdMOjV6N{izN|E>
Z-138 MVHDfZRwfG:6aXOgRZN{[Xl? NV\4d2VwPzJiaB?= NHjIb3dFVVOR NHfscnpKSzVyPUCuNFE{KM7:TR?= Mn;SNlU5Pzh|M{G=
H9 MYrDfZRwfG:6aXOgRZN{[Xl? NFvqWmE4OiCq M3zYbmROW09? MmPTTWM2OD1yLk[g{txO NWTB[oRTOjV6N{izN|E>
HH M{XveWN6fG:2b4jpZ{BCe3OjeR?= M33U[FczKGh? MlXaSG1UVw>? NYnzR4h{UUN3ME2wMlch|ryP MUOyOVg4QDN|MR?=
DND41 M1fudmN6fG:2b4jpZ{BCe3OjeR?= NV7CcWdXPzJiaB?= NGLkU4ZFVVOR M2jRZmlEPTB;MD6xJO69VQ>? MVeyOVg4QDN|MR?=
CCL119 NHfud5dEgXSxdH;4bYMhSXO|YYm= M3yzN|czKGh? M2TqVmROW09? MUTJR|UxRTBwME[yJO69VQ>? NWK2W3l5OjV6N{izN|E>
J.Cam 1.6 MnfLR5l1d3SxeHnjJGF{e2G7 MmjiO|IhcA>? Mnf0SG1UVw>? MXrJR|UxRTBwMUC1JO69VQ>? M1WzPFI2QDd6M{Ox
Sup-T1 NU\CNVNtS3m2b4TvfIlkKEG|c3H5 NV\mVVRlPzJiaB?= NIWzc2hFVVOR NIrLZVhKSzVyPUKuNVQzKM7:TR?= MXeyOVg4QDN|MR?=
Tib 152 MkLHR5l1d3SxeHnjJGF{e2G7 MknVO|IhcA>? Mnj5SG1UVw>? NYL3WlIyUUN3ME2wMlgh|ryP NWDSPZU6OjV6N{izN|E>
MCF7 NFmybHNHfW6ldHnvckBCe3OjeR?= M3vQOVUh|ryP NGXhNY8zPCCq NVHVZ2FiTE2VTx?= MmfPTY5lfWOnczDHNk9OKGG{cnXzeC=> NELlRnAzPTh|NESwNS=>
MDA-MB-231 M3jOO2Z2dmO2aX;uJGF{e2G7 NHPzZm82KM7:TR?= M2rrdVI1KGh? MmTmSG1UVw>? MkXYTY5lfWOnczDHN{9OKGG{cnXzeC=> NITjOZczPTh|NESwNS=>
MCF7 NIi1UGxHfW6ldHnvckBCe3OjeR?= MYO1JO69VQ>? NHf1RXozPCCq M1nZeWROW09? NFPNVY5F\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOS:FRFOy MlfVNlU5OzR2MEG=
MCF7 M3jFemZ2dmO2aX;uJGF{e2G7 MWS1JO69VQ>? M3rHZ|I1KGh? MknzSG1UVw>? NFrjWWZF\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gR2RMOg>? NUXSfldPOjV6M{S0NFE>
MCF7 MkTDSpVv[3Srb36gRZN{[Xl? MWe1JO69VQ>? NUnzNXdZOjRiaB?= MXXEUXNQ MUnE[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZiY4njcIlvKEJz MVSyOVg{PDRyMR?=
MCF7 MUjGeY5kfGmxbjDBd5NigQ>? MUm1JO69VQ>? Mn7iNlQhcA>? M1PhO2ROW09? MknZTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE> MYWyOVg{PDRyMR?=
MCF7 MWrGeY5kfGmxbjDBd5NigQ>? M4THNlUh|ryP M136XFI1KGh? M3fmXGROW09? NYH5UXRGUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzPyCNaYCx M3qxSVI2QDN2NECx
MDA-MB-231 MlrmSpVv[3Srb36gRZN{[Xl? NWqyc2FSPSEQvF2= MlnWNlQhcA>? NULDfIEzTE2VTx?= NYXO[2s1TGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJGNFUzFxQ1TDNi=> M{\XUFI2QDN2NECx
MDA-MB-231 M{fNfGZ2dmO2aX;uJGF{e2G7 M2XyV|Eh|ryP NG\YN3czPCCq M1\IVmROW09? Ml7QTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET|I> MUiyOVg{PDRyMR?=
MDA-MB-231 M13xcmZ2dmO2aX;uJGF{e2G7 NV\JSZZSPSEQvF2= MWmyOEBp M1XBcmROW09? MnP6SIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIHP5Z4xqdiCEMR?= NVL0cYVYOjV6M{S0NFE>
MDA-MB-231 MXnGeY5kfGmxbjDBd5NigQ>? MoTNOUDPxE1? MkfpNlQhcA>? NVqwOHhQTE2VTx?= NG\QdJhKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFIyKFejZkGvR4lxOQ>? Moq1NlU5OzR2MEG=
MDA-MB-231 MnrLSpVv[3Srb36gRZN{[Xl? NXTUbVdoPSEQvF2= MXiyOEBp NGDjW4hFVVOR NVTkW5YzUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJAzPyCNaYCx M3vsWlI2QDN2NECx
MDA-MB-231 NXnoV5puTnWwY4Tpc44hSXO|YYm= MW[1JO69VQ>? NWnPS4RFOjRiaB?= MVjEUXNQ MoLpTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIIC1Ny=> MmqwNlU5OzR2MEG=
MCF7 NV2xTYdiSXCxcITvd4l{KEG|c3H5 NEP2Zoo2KM7:TR?= MXOyOEBp NVPIbW5wTE2VTx?= MWnJcoR2[2W|IHHwc5B1d3SrYzDk[YF1cA>? NGXYTXozPTh|NESwNS=>
MDA-MB-231 MnzKRZBweHSxc3nzJGF{e2G7 MY[1JO69VQ>? M{e5RVI1KGh? MVPEUXNQ MVnJcoR2[2W|IHHwc5B1d3SrYzDk[YF1cA>? NEC2SYwzPTh|NESwNS=>
MCF7 M1HLOWZ2dmO2aX;uJGF{e2G7 NInDcHUyKM7:TR?= M1rPbFczKGh? NVH1N2ZbTE2VTx?= M{DYfWlv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?= MkfGNlU5OzR2MEG=
MDA-MB-231 MYHGeY5kfGmxbjDBd5NigQ>? M4TGTFEh|ryP M4P4flczKGh? MkfJSG1UVw>? MUXJcoR2[2W|IHH1eI9xcGGpaXOg[IVifGh? NXTzRoZOOjV6M{S0NFE>
U-2 OS M1TYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPHZWdjPTBizszN NYKzc|A2OjRiaB?= NWHpcJVITE2VTx?= M4\PdWlEPTB;MU[uOkDPxE1? MmjHNlU4QTJ6MUG=
MG-63 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHi2SnY2OCEQvF2= NF[wcpgzPCCq NH76NoRFVVOR MYnJR|UxRTlwNTFOwG0> NFTyNWEzPTd7MkixNS=>
U-2 OS MW\BdI9xfG:|aYOgRZN{[Xl? Ml60OUDPxE1? NFnGdmIzPCCq M3TjdWROW09? NFnDVpdKdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp M3z3OVI2Pzl{OEGx
MG-63 MX;BdI9xfG:|aYOgRZN{[Xl? M3mxWVUh|ryP MkeyNlQhcA>? MXHEUXNQ M1Tkdmlv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIg> MYKyOVc6OjhzMR?=
U-2 OS NI\DWJRHfW6ldHnvckBCe3OjeR?= M4TtWlUh|ryP MWKyOEBp M3Lkb2ROW09? MVnQdo9ud3SnczDheZRweGijZ3njJINmdGxiZHXheIg> NELtb3kzPTd7MkixNS=>
MG-63 M3n5[GZ2dmO2aX;uJGF{e2G7 M330TlUh|ryP Mk[2NlQhcA>? M4SwfGROW09? M3;zeXBzd22xdHXzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? M2DHTFI2Pzl{OEGx
PANC-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\k[2Y2OCEQvF2= MmjyNlQhcA>? NIK1PJZFVVOR MX;JR|UxRTdwMTFOwG0> MXSyOVY{OjJ{NR?=
BxPC-3 NUf6NJNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:1NEDPxE1? NWO2WVNMOjRiaB?= MnPnSG1UVw>? M2TScWlEPTB;Nj64JO69VQ>? M{W4bVI2PjN{MkK1
PANC-1 MkTMSpVv[3Srb36gRZN{[Xl? M1XiTFUh|ryP NV\kXJJsOjRiaB?= MkHtSG1UVw>? MnizTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDpckBIOi:PIIDoZZNm NI\xOlYzPTZ|MkKyOS=>
BxPC-3 MUjGeY5kfGmxbjDBd5NigQ>? M3TUOVUh|ryP MnjNNlQhcA>? NGDzZmtFVVOR M2f1PGlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hTzJxTTDwbIF{\Q>? NWPiWW5rOjV4M{KyNlU>
PANC-1 MX;GeY5kfGmxbjDBd5NigQ>? NXjZUVFtPSEQvF2= M{\PcVI1KGh? M4W5OmROW09? NWP4bHBlUW6mdXPld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? MWCyOVY{OjJ{NR?=
BxPC-3 M3OzRWZ2dmO2aX;uJGF{e2G7 MnjwOUDPxE1? NYXkOpE1OjRiaB?= NGPyd|FFVVOR M1;XZ2lv\HWlZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp NGjhRZIzPTZ|MkKyOS=>
SKOV3 NGHWT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m2U|ExOCEQvF2= Mn;xNlQhcA>? MV;EUXNQ MUPJR|UxRTJyLkS4JO69VQ>? M1zlN|I2PjJ2N{Ww
OVCAR4 Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVGxNFAh|ryP NGLETW0zPCCq MkSzSG1UVw>? M2HXOmlEPTB;MkKuNVMh|ryP MXOyOVYzPDd3MB?=
SKOV3 MUPGeY5kfGmxbjDBd5NigQ>? MUS1JO69VQ>? MnnEO|IhcA>? NWXVTG01TE2VTx?= MmC1TY5lfWOnczDHNk9OKGG{cnXzeC=> NH;USWszPTZ{NEe1NC=>
OVCAR4 M1PLNWZ2dmO2aX;uJGF{e2G7 Mln5OUDPxE1? NIjnbIc4OiCq MWPEUXNQ MYXJcoR2[2W|IFeyM20h[XK{ZYP0 NWHqXJFGOjV4MkS3OVA>
SKOV3 NV[zTWN3SXCxcITvd4l{KEG|c3H5 M3nLelUh|ryP M1zXS|I1KGh? NXe2WWxyTE2VTx?= M1jKbmlv\HWlZYOgZZBweHSxc3nz NXizblRSOjV4MkS3OVA>
OVCAR4 MmDnRZBweHSxc3nzJGF{e2G7 NHLkdpE2KM7:TR?= M3rjWlI1KGh? MV;EUXNQ M1uzVmlv\HWlZYOgZZBweHSxc3nz M{DKSlI2PjJ2N{Ww
AGS M1T6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYqyOUDPxE1? MoPlNlQhcA>? MUDEUXNQ Mmr2TWM2OD1zOT6wPUDPxE1? NInLN20zPTZyOUmyNy=>
NCI-N78 MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXPSnhSOjVizszN MX[yOEBp NHm2ephFVVOR MnXETWM2OD1{Nj6zN{DPxE1? MnPKNlU3ODl7MkO=
AGS MXTBdI9xfG:|aYOgRZN{[Xl? NX73UHFrPSEQvF2= NUnuTGhIOjRiaB?= Mn\OSG1UVw>? MU\JcoR2[2W|IHHwc5B1d3Orcx?= MkDSNlU3ODl7MkO=
NCI-N78 MnvlRZBweHSxc3nzJGF{e2G7 M3PQ[FUh|ryP MX:yOEBp M4G5TmROW09? NIDjboVKdmS3Y3XzJIFxd3C2b4Ppdy=> MoXtNlU3ODl7MkO=
AGS M3zYRWZ2dmO2aX;uJGF{e2G7 NFK3SJk2KM7:TR?= NY\CRZRtOjRiaB?= NIXybYRFVVOR Moe1TY5lfWOnczD0bIUh[XW2b4DoZYd6 MnzhNlU3ODl7MkO=
NCI-N78 MXHGeY5kfGmxbjDBd5NigQ>? M1TLNFUh|ryP Mn7vNlQhcA>? NIj3blFFVVOR MUTJcoR2[2W|IITo[UBifXSxcHjh[5k> NXfoZ5pXOjV4MEm5NlM>
HSC-3 NHrCdG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjZNUDPxE1? NFKzfYo1QCCq MnH5TWM2OD1yLkW0JO69VQ>? M2TaZlI2OzZ4MUSz
GB30 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzlW|hzOSEQvF2= MUW3JIQ> NHju[otFVVOR MVHJR|UxRTBwMEGxJO69VQ>? NWDrWIpQOjVzME[0Nlg>
GB9 M3;JeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCxJO69VQ>? MYe3JIQ> MlPTSG1UVw>? NEn3SplKSzVyPUCuNFI1KM7:TR?= NX7ZboFlOjVzME[0Nlg>
GB169 M2mzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DwTVEh|ryP NG[3W|A4KGR? NX;xcHdvTE2VTx?= NIW0U|FKSzVyPUCuNFMzKM7:TR?= M{XNXlI2OTB4NEK4
T24 MXvGeY5kfGmxbjDBd5NigQ>? M4DrNFEh|ryP MUm0PEBp MVvEUXNQ NWT5W2U3UW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> NIn4S2UzOzRyM{[zNy=>
RT4 MUXGeY5kfGmxbjDBd5NigQ>? MnmxNUDPxE1? NFzxZVQ1QCCq M1zmNWROW09? NInwTpFKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 NUTMPZBkOjN2MEO2N|M>
UM-UC-3 MlHUSpVv[3Srb36gRZN{[Xl? NYDET5ZxOSEQvF2= NGfscJk1QCCq NVrMTmdlTE2VTx?= M3S4dGlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MV6yN|QxOzZ|Mx?=
T24 NHrIZWdCeG:ydH;zbZMhSXO|YYm= NHnEdIQ{NjF4IN88US=> MWi5OkBp MWDEUXNQ MoXuTWM2OD1yLkCzNFYh|ryP MorvNlM1ODN4M{O=
RT4 MV7BdI9xfG:|aYOgRZN{[Xl? M37GblMvOTZizszN MlLDPVYhcA>? M{jQNGROW09? M3LobmlEPTB;MD6xNVk5KM7:TR?= NWfuOWtLOjN2MEO2N|M>
UM-UC-3 MY\BdI9xfG:|aYOgRZN{[Xl? MWCzMlE3KM7:TR?= MWW5OkBp MmHLSG1UVw>? NYTQUWpvUUN3ME2wMlA1PDlizszN NFThTmUzOzRyM{[zNy=>
OVCAR-5 MUTGeY5kfGmxbjDBd5NigQ>? M1vyZVUxKG6P MoPrTY5pcWKrdIOgZ4VtdCCvaXfyZZRqd25? M1nuWFI{OzN2M{K3
SKOV3ip2 NGTiSmRHfW6ldHnvckBCe3OjeR?= NXXOS4hkPTBibl2= NX;2fWc5UW6qaXLpeJMh[2WubDDtbYdz[XSrb36= NGDxZ2YzOzN|NEOyOy=>
S462 Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjjSVlMOTByIN88US=> MY[3NkBp M1W1TWROW09? NYnjOoFqSXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?= Mo\ENlM{OjhzMUS=
2884 MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\YNVAxKM7:TR?= MkCxO|IhcA>? MlzkSG1UVw>? M4X3WmF1fGWwdXH0[ZMh[2WubDDndo94fGh? MWiyN|MzQDFzNB?=
2885 M1rSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXexNFAh|ryP M2HsU|czKGh? MYXEUXNQ NGTDSWxCfHSnboXheIV{KGOnbHyg[5Jwf3Sq NHTORpQzOzN{OEGxOC=>
CRL-2396 NYXicZRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\KXVExOCEQvF2= MV33ZZRmeg>? M{DHZmlEPTB;MD6wPVIh|ryP NWHIU4YxOjNzNUO1NlQ>
TIB-48 NVf3WnQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmniNVAxKM7:TR?= MnTle4F1\XJ? M3HNU2lEPTB;MD6wPFgh|ryP MUCyN|E2OzV{NB?=
CRL-2396 Mn65R5l1d3SxeHnjJGF{e2G7 NWDV[Fh2OSEQvF2= MnfMOFghcA>? MUH3ZZRmeg>? NXTBXYEyUW6mdXPld{BieG:ydH;zbZM> NFPWO2IzOzF3M{WyOC=>
TIB-48 MmXCR5l1d3SxeHnjJGF{e2G7 NFjDO4QyKM7:TR?= MV20PEBp NVe2Zoc3f2G2ZYK= MYPJcoR2[2W|IHHwc5B1d3Orcx?= MlzENlMyPTN3MkS=
AGS M{jrWmN6fG:2b4jpZ{BCe3OjeR?= M1uxZlAvPSEQvF2= NVu4UY1vOjRiaB?= MYjEUXNQ MXXE[YNz\WG|ZYOgZ4VtdCC|dYL2bZZidA>? NFW1OHIzOjl5Mk[xNS=>
FLO-1 NGjiNJVEgXSxdH;4bYMhSXO|YYm= NVvxZXV2OC53IN88US=> NHPVNYYzPCCq M4\JcGROW09? M{\Jd2Rm[3KnYYPld{Bk\WyuIIP1dpZqfmGu NW\hRpo{OjJ7N{K2NVE>
OE33 NXLMSI1LS3m2b4TvfIlkKEG|c3H5 M4LaUFAvPSEQvF2= NYTQRXB4OjRiaB?= NITUVWZFVVOR NVvhT2FkTGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy= NETQZ4YzOjl5Mk[xNS=>
SKLMS MljsR5l1d3SxeHnjJGF{e2G7 MmPZO|Uhdk1? NYq0bWVrQTZiaB?= MnvZTY5lfWOnczDhdI9xfG:|aYO= NYjJ[Gh4OjJ6MkG5PVc>
Leio285 MYHDfZRwfG:6aXOgRZN{[Xl? NGPrU2I4PSCwTR?= MUC5OkBp NY[0T2piUW6mdXPld{BieG:ydH;zbZM> M{TTc|IzQDJzOUm3
Mes-Sa M{fRemN6fG:2b4jpZ{BCe3OjeR?= NF3pTIY4PSCwTR?= MWC5OkBp M2fGZmlv\HWlZYOgZZBweHSxc3nz NV\NRWtyOjJ6MkG5PVc>
DAOY MkCwR5l1d3SxeHnjJGF{e2G7 MnjxNVAh|ryP Mln2O|IhcA>? MVvEUXNQ NYC5eFJTUUN3ME2wMlA1KM7:TR?= NYrSeJlmOjJ4NkmzN|U>
IMR32 M4LT[WN6fG:2b4jpZ{BCe3OjeR?= M3T5[lExKM7:TR?= MXW3NkBp NEXKOZNFVVOR MY\JR|UxRTBwMEOg{txO NYDtVXZ{OjJ4NkmzN|U>
Molt-4 MnvyR5l1d3SxeHnjJGF{e2G7 M1jSTFExKM7:TR?= NYi1fFVNPzJiaB?= M1K0NmROW09? MnT2TWM2OD1yLkCyJO69VQ>? M2HoZ|IzPjZ7M{O1
MOLM-13 NYjLN3BxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPhNYI{KM7:TR?= NYHkWG9MPzJiaB?= NF\vWIRFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 M2HueFIzPDh6MkS5
HL-60 MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[3WVMh|ryP M{m4T|czKGh? MWrEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NXm1T|FCOjJ2OEiyOFk>
MV4-11 Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\4[|Mh|ryP NWrJPFAzPzJiaB?= MYjEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NHTCbHAzOjR6OEK0PS=>
SKM-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:zJO69VQ>? M2POelczKGh? M1zDVWRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= MlLVNlI1QDh{NEm=
SH2 NUXzTGtCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\MN{DPxE1? NYXSV5RIPzJiaB?= M{T3cmRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= MYSyNlQ5QDJ2OR?=
NOMO-1 M{P5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfzN2Y4OyEQvF2= MYK3NkBp MlzpSIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NVHWOW46OjJ2OEiyOFk>
OCL-AML2 MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvmUmtKOyEQvF2= NYrwWnRmPzJiaB?= MUTEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 M3f3eFIzPDh6MkS5
PL-21 M3zHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPxclc{KM7:TR?= MWO3NkBp NGPlXlNFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 M4LmSVIzPDh6MkS5
KG-1 M4HmWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDhN{DPxE1? MljwO|IhcA>? NELyd2JFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 MkHyNlI1QDh{NEm=
A172 NXf3VotQS3m2b4TvfIlkKEG|c3H5 M3TXTFExOCEQvF2= NUDoS3JrOjRiaB?= NGiyToRFVVOR NUX1[41{UUN3ME2wMlEzOCEQvF2= NEK3c3QzOjJ5NEO5PS=>
U87 MnrqR5l1d3SxeHnjJGF{e2G7 MmroNVAxKM7:TR?= M{\UeVI1KGh? NELrSm9FVVOR NYnaSHpVUUN3ME2wMlExPSEQvF2= MWCyNlI4PDN7OR?=
U251 MmfaR5l1d3SxeHnjJGF{e2G7 NHHOe|IyODBizszN NHvKeJczPCCq M{DMc2ROW09? M{XRemlEPTB;MD6xNFAh|ryP M{G2WVIzOjd2M{m5
T98 NGDtNVdEgXSxdH;4bYMhSXO|YYm= MUOxNFAh|ryP Mor6NlQhcA>? NGTzPYVFVVOR NIHwephKSzVyPUCuNVI2KM7:TR?= MlHENlIzPzR|OUm=
LN18 NFHHe2tEgXSxdH;4bYMhSXO|YYm= NUjZZ5YxOTByIN88US=> MVeyOEBp NGXsN3ZFVVOR NI\Db|BKSzVyPUCuNlExKM7:TR?= MWOyNlI4PDN7OR?=
LN443 M3zaUmN6fG:2b4jpZ{BCe3OjeR?= M{S5U|ExOCEQvF2= M4jxXFI1KGh? M4PrbmROW09? M{\FeGlEPTB;MD6yNlAh|ryP NWqyfXA{OjJ{N{SzPVk>
HF66 MmTiR5l1d3SxeHnjJGF{e2G7 MYCxNFAh|ryP MXiyOEBp MUTEUXNQ NFLR[XNKSzVyPUCuNlI2KM7:TR?= M3;uUFIzOjd2M{m5
HF2303 Ml:3R5l1d3SxeHnjJGF{e2G7 NWXRfmU2OTByIN88US=> M1K0WlI1KGh? NFf3cI5FVVOR M{G1O2lEPTB;MD6wOlAh|ryP NUDpbGZoOjJ{N{SzPVk>
HF2359 Mn3ZR5l1d3SxeHnjJGF{e2G7 NIOxfnQyODBizszN NH:xNXUzPCCq M4\ZV2ROW09? NELQVVhKSzVyPUCuNFYxKM7:TR?= NIPldJUzOjJ5NEO5PS=>
HF2414 MY\DfZRwfG:6aXOgRZN{[Xl? NHy0S|cyODBizszN M2HTblI1KGh? M3e2PWROW09? MWPJR|UxRTBwMEiwJO69VQ>? M323UFIzOjd2M{m5
A-673 NYLFbnAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[1WIJLOTBizszN NV7jRop{QTZiaB?= MmHHSG1UVw>? M3fycWlEPTB;MD6wN|Ih|ryP M2j3S|IyPDR6NUmx
TC-32 M3W5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnvNVAh|ryP Mmr2PVYhcA>? M{Cwb2ROW09? MlXJTWM2OD1yLkCzPUDPxE1? M33xZ|IyPDR6NUmx
TC-71 M1PhV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHINVAh|ryP MXS5OkBp NWj2O4I1TE2VTx?= NEDHSFBKSzVyPUCuNVAzKM7:TR?= NFXm[3QzOTR2OEW5NS=>
SK-N-MC M{D6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL4TXEyOCEQvF2= M3rGPVk3KGh? NWDuRWw1TE2VTx?= M1n2NmlEPTB;MD6wO|Ih|ryP M{XQXlIyPDR6NUmx
CHLA-9 NWPzdJlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jN[VExKM7:TR?= Mo\WPVYhcA>? M{\SSmROW09? NVK4RZZLUUN3ME2wMlAyQCEQvF2= MmPqNlE1PDh3OUG=
CHLA-10 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOxNEDPxE1? M1vIc|k3KGh? MkX6SG1UVw>? NVznWXVSUUN3ME2wMlA3OCEQvF2= NGLLVWYzOTR2OEW5NS=>
CHLA-25 NGXldpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXz5ZlNMOTBizszN MWS5OkBp M2\j[2ROW09? Ml;0TWM2OD1yLkG2PEDPxE1? MXSyNVQ1QDV7MR?=
CHLA-32 M3LQU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq5UYVzOTBizszN MlnhPVYhcA>? M3LuSGROW09? M1;tWmlEPTB;MD6xN|Yh|ryP NI\1cXIzOTR2OEW5NS=>
CHLA-56 NYDEeWtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUWxNEDPxE1? MX25OkBp MXjEUXNQ NEHhfWNKSzVyPUGwJO69VQ>? MX2yNVQ1QDV7MR?=
CHLA-258 Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2joRlExKM7:TR?= NUH5[FhJQTZiaB?= M3;mWmROW09? MYDJR|UxRTBwMUOyJO69VQ>? M4LoS|IyPDR6NUmx
COG-E-352 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf0e|J1OTBizszN MVe5OkBp NHHGNpRFVVOR NXnCdW1WUUN3ME2wMlA1OyEQvF2= M{LYRlIyPDR6NUmx
CHLA-90 M3XHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXuZ3oyOCEQvF2= MXO5OkBp NW\kVlU6TE2VTx?= NU\DOlZYUUN3ME2wMlA3OSEQvF2= M2rlWlIyPDR6NUmx
CHLA-119 NX33XYxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYGxNEDPxE1? MXW5OkBp NEf0V21FVVOR MYPJR|UxRTBwMEKyJO69VQ>? M1TSZlIyPDR6NUmx
CHLA-122 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH4cGJXOTBizszN NGXqO|I6PiCq MVfEUXNQ MoPyTWM2OD1yLkCxPUDPxE1? NFThVmszOTR2OEW5NS=>
CHLA-136 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7qOmozOTBizszN NFqyfVg6PiCq MnPpSG1UVw>? M{PFfGlEPTB;MD6wN|kh|ryP Ml;6NlE1PDh3OUG=
CHLA-140 NEfu[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TQelExKM7:TR?= MU[5OkBp M3\DNGROW09? M2XwW2lEPTB;MD6wNlYh|ryP NVPvdYRyOjF2NEi1PVE>
LA-N-6 M{fv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXEZmtUOTBizszN NFTyNXc6PiCq M{LJb2ROW09? MnnZTWM2OD1yLkC1OEDPxE1? Mk\SNlE1PDh3OUG=
NB-1643 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYi5[JlbOTBizszN NH7PdlM6PiCq M2rpUmROW09? MXnJR|UxRTBwMEO3JO69VQ>? Mo\0NlE1PDh3OUG=
NB-EBc1 MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33xNVExKM7:TR?= NH\SV|I6PiCq NI[4UY5FVVOR M3Lxc2lEPTB;MD6wOVAh|ryP NHOwb3EzOTR2OEW5NS=>
SK-N-BE-1 M4\rb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NICyXnQyOCEQvF2= NUHnNGgyQTZiaB?= MlPwSG1UVw>? NWLG[VZMUUN3ME2wMlAzQCEQvF2= MlToNlE1PDh3OUG=
SK-N-BE-2 NID2UnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7jbJAyOCEQvF2= Mk[wPVYhcA>? NYXBNmV2TE2VTx?= NVvycm1zUUN3ME2wMlA{PiEQvF2= MkfKNlE1PDh3OUG=
SMS-KAN M3\1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorGNVAh|ryP MWC5OkBp M33ZSWROW09? M3LVVmlEPTB;MD6wN|Qh|ryP NEXnVWQzOTR2OEW5NS=>
SMS-KANR NYH3bWtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPudIkyOCEQvF2= NEfwboY6PiCq MoHHSG1UVw>? NGPDVJlKSzVyPUCuNFI3KM7:TR?= M2fWOFIyPDR6NUmx
SMS-KCN M3O3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFKwfZoyOCEQvF2= MnrGPVYhcA>? M3z5TGROW09? NYPMO45YUUN3ME2wMlAyQSEQvF2= NUjmR2RCOjF2NEi1PVE>
SMS-KCNR M4D4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYftVXlUOTBizszN MUe5OkBp MWLEUXNQ MljkTWM2OD1yLkCxNEDPxE1? MYiyNVQ1QDV7MR?=
SMS-LHN M2iw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTsdXd1OTBizszN MWi5OkBp NITQVGlFVVOR NYXXNXhWUUN3ME2wMlA{OiEQvF2= MYKyNVQ1QDV7MR?=
SMS-MSN MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWT6Xo1ROTBizszN M1nDc|k3KGh? MlXBSG1UVw>? MojQTWM2OD1yLkCyNkDPxE1? M3vJNlIyPDR6NUmx
SMS-SAN NU\D[Vg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTKNVAh|ryP MUi5OkBp NVLVUlFNTE2VTx?= NXPy[ZBmUUN3ME2wMlAzOCEQvF2= M3vzfFIyPDR6NUmx
Granta-4 MW\DfZRwfG:6aXOgRZN{[Xl? MVGxNEDPxE1? MlHiO{Bl NWTEWlJZUUN3ME2wMlA1OCEQvF2= MWOyNVI6OTh4Nx?=
DB M1G3cGN6fG:2b4jpZ{BCe3OjeR?= MorLNVAh|ryP MYi3JIQ> NWDxVGJnUUN3ME2wMlA1OiEQvF2= MVGyNVI6OTh4Nx?=
RL M2TYbGN6fG:2b4jpZ{BCe3OjeR?= NUjROnY5OTBizszN MXm3JIQ> MV3JR|UxRTBwMEG1JO69VQ>? M4[2WFIyOjlzOE[3
K562 NEK3bINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnZNVAh|ryP NID6UFY6PiCq NIC5N|FKSzVyPUCuNFg4KM7:TR?= NYi1dHZtOjFyOUG2N|M>
LAMA-84 NV\1VoFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[5enBXOTBizszN NIXP[lU6PiCq M2XUUWlEPTB;MD6wOVch|ryP MknDNlExQTF4M{O=
MM15 M1GxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\Db3pwPCEQvF2= MWG3NkBp MWXEUXNQ MV;JR|UxRTBwMUOg{txO NEi0[YczODN6Mki0OC=>
OPM1 NV\LWlQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLWR4dZPCEQvF2= MUW3NkBp MYDEUXNQ NXHsPXA{UUN3ME2wMlA{KM7:TR?= NYrMfHg5OjB|OEK4OFQ>
RPM1 Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\wPZA1KM7:TR?= M3vCdVczKGh? M1LuW2ROW09? Mn6zTWM2OD1zMD6zNkDPxE1? MnPNNlA{QDJ6NES=
INA6 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljpOEDPxE1? NFz5OYY4OiCq NVy2RlVSTE2VTx?= MYDJR|UxRTBwMECyJO69VQ>? M1jVPFIxOzh{OES0
OPM2 M1LGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHGfok1KM7:TR?= M3HoPFczKGh? NVT2UlRXTE2VTx?= Ml3UTWM2OD12LkO3JO69VQ>? NYq1OpJWOjB|OEK4OFQ>
MM1R NV;0UpZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvwOEDPxE1? MX23NkBp M{DFPGROW09? MlfxTWM2OD1zLk[4JO69VQ>? NXraXmc6OjB|OEK4OFQ>
DOX40 NXmzdIo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\nbIhtPCEQvF2= M2PaV|czKGh? Mk\hSG1UVw>? NH;JVJRKSzVyPUWuOFgh|ryP NWTzb2xlOjB|OEK4OFQ>
LR5 M2LMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLMZmw1KM7:TR?= MoDYO|IhcA>? MnXJSG1UVw>? MoDLTWM2OD1{LkWzJO69VQ>? NUPoXYN1OjB|OEK4OFQ>
U266 NF3DS2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPlZmxYPCEQvF2= M13qd|czKGh? NGTPZW1FVVOR M2P1RmlEPTB;MT60N{DPxE1? MmDWNlA{QDJ6NES=
RD NI[0VHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCxNEDPxE1? NYq4OXdmQTZiaB?= NH3xPVFKSzVyPUCuNlI5KM7:TR?= MnrWNlAyODh|M{i=
Rh41 NEXmcWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1e1b|ExKM7:TR?= NGLvRY86PiCq MoPFTWM2OD1yLkC5NEDPxE1? MVOyNFExQDN|OB?=
Rh30 Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWOwS5JKOTBizszN NH7QS4U6PiCq NIHUUpBKSzVyPUCuNlMxKM7:TR?= NV3Oc5V5OjBzMEizN|g>
BT-12 M1yzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr3WI1{OTBizszN M3ryVFk3KGh? NEP3NWtKSzVyPUCuNFYxKM7:TR?= NYHNWHpyOjBzMEizN|g>
CHLA-266 NHfaRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXiNVAh|ryP M1SxeVk3KGh? MULJR|UxRTBwMEeyJO69VQ>? MmrkNlAyODh|M{i=
TC-71 NFT2RoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O1N|ExKM7:TR?= M1PLV|k3KGh? M33acmlEPTB;MD6xNFIh|ryP NHzpXHgzODFyOEOzPC=>
SJ-GBM2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHrR4kyOCEQvF2= NYmxT3g6QTZiaB?= NHjUdGtKSzVyPUCuNFUxKM7:TR?= MkXkNlAyODh|M{i=
NALM-6 NVfVc5ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fZcVExKM7:TR?= NX7jXppYQTZiaB?= MnPlTWM2OD1yLkC2NkDPxE1? M3zWSVIxOTB6M{O4
COG-LL-317 NUPQVmdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LKdFExKM7:TR?= MmTkPVYhcA>? MnrNTWM2OD1yLkC0O{DPxE1? MmDsNlAyODh|M{i=
RS4-11 MknjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPxNVAh|ryP MYO5OkBp NHvJdHNKSzVyPUCuNFE5KM7:TR?= NY\pZ4VkOjBzMEizN|g>
MOLT-4 Mn24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rXblExKM7:TR?= M3;sTlk3KGh? NUnoVopGUUN3ME2wMlAzPiEQvF2= MlPENlAyODh|M{i=
CCRF-CEM NIXZS49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD4NVAh|ryP NVG3S|d2QTZiaB?= M3P3[GlEPTB;MD6wPVQh|ryP NFPMZm4zODFyOEOzPC=>
Kasumi-1 M1q4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXSxTWx7OTBizszN NUXPVlRvQTZiaB?= MlSxTWM2OD1yLkGwN{DPxE1? MnTHNlAyODh|M{i=
Karpas-299 MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFy4fVQyOCEQvF2= NIrWXG06PiCq MYjJR|UxRTBwMEO4JO69VQ>? NXvDN4N4OjBzMEizN|g>
Ramos-RA1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Xu[|ExKM7:TR?= MmG1PVYhcA>? NWT3TnJuUUN3ME2wMlEzPyEQvF2= M{DQd|IxOTB6M{O4

... Click to View More Cell Line Experimental Data

In vivo MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

Protocol

Kinase Assay:[1]
+ Expand

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:[2]
+ Expand
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • Dosages: ~30 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (52.03 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 15% Captisol 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 518.92
Formula

C27H20ClFN4O4

CAS No. 1028486-01-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02860000 Not yet recruiting Estrogen Receptor Negative|Estrogen Receptor Positive|HER2/Neu Negative|Postmenopausal|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 2016 Phase 2
NCT02812056 Not yet recruiting Malignant Neoplasms of Digestive Organs|Malignant Neoplasms of Female Genital Organs|Malignant Neoplasms of Lip Oral Cavity and Pharynx|Malignant Neoplasms of Male Genital Organs M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. September 2016 Phase 1
NCT02700022 Recruiting Diffuse Large B-cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma UNC Lineberger Comprehensive Cancer Center|Millennium Pharmaceuticals, Inc. July 2016 Phase 1
NCT02719691 Recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver May 2016 Phase 1
NCT02560025 Recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Takeda December 2015 Phase 2
NCT02551055 Active, not recruiting Neoplasms, Advanced or Metastatic Millennium Pharmaceuticals, Inc.|Takeda October 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Alisertib (MLN8237) | Alisertib (MLN8237) supplier | purchase Alisertib (MLN8237) | Alisertib (MLN8237) cost | Alisertib (MLN8237) manufacturer | order Alisertib (MLN8237) | Alisertib (MLN8237) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID